China’s Senlang reaches license option deal with Tempest for ex-China rights to a BCMA/GPRC5D-targeted in vivo CAR-T candidate delivered by a CD7-targeted lentiviral vector, plus its vector platform and other in vivo CAR-T assets.
China’s Senlang reaches license option deal with Tempest for ex-China rights to a BCMA/GPRC5D-targeted in vivo CAR-T candidate delivered by a CD7-targeted lentiviral vector, plus its vector platform and other in vivo CAR-T assets.